Literature DB >> 27768254

Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.

Marlies Bekaert1, D Margriet Ouwens1,2,3, Tina Hörbelt2,3, Frederique Van de Velde1, Pia Fahlbusch2,3, Daniella Herzfeld de Wiza2,3, Yves Van Nieuwenhove4, Patrick Calders5, Marleen Praet6, Anne Hoorens6, Anja Geerts7, Xavier Verhelst7, Jean-Marc Kaufman1, Bruno Lapauw1.   

Abstract

OBJECTIVE: This study aimed to evaluate whether circulating levels and/or visceral adipose tissue (VAT) expression of recently described adipokines associate with histopathological severity of nonalcoholic fatty liver disease (NAFLD), independent of obesity and insulin resistance.
METHODS: Serum levels of adiponectin, omentin, chemerin, monocyte chemoattractant protein-1, and secreted frizzled-related protein 4 were measured using enzyme-linked immunosorbent assay in 81 patients with obesity and NAFLD and 18 lean control subjects. Expression in VAT was measured using real-time PCR and histopathological grading was scored using the NAFLD activity score (NAS).
RESULTS: When NAFLD patients were subdivided into groups with simple steatosis, borderline nonalcoholic steatohepatitis (NASH), and NASH, adiponectin serum levels and omentin expression were lower in NASH versus simple steatosis patients. Serum adiponectin was generally lower with higher histopathological grading. Chemerin VAT expression was negatively associated with NAS (r = -0.331, P = 0.022) and steatosis score (r = -0.335, P = 0.020), independent of age, BMI, and HOMA-IR. In addition, adjusting for chemerin VAT expression in a multivariate model explained part of the association between NAS and HOMA-IR.
CONCLUSIONS: These findings suggest that lower VAT expression of chemerin in patients with obesity may be involved in the pathophysiology of hepatic steatosis, potentially by modulating the link between insulin resistance and NAFLD.
© 2016 The Authors Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27768254     DOI: 10.1002/oby.21674

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  10 in total

1.  Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Authors:  S Lefere; F Van de Velde; L Devisscher; M Bekaert; S Raevens; X Verhelst; Y Van Nieuwenhove; M Praet; A Hoorens; C Van Steenkiste; H Van Vlierberghe; B Lapauw; A Geerts
Journal:  Int J Obes (Lond)       Date:  2017-05-02       Impact factor: 5.095

2.  The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes.

Authors:  Tina Hörbelt; Christopher Tacke; Mariya Markova; Daniella Herzfeld de Wiza; Frederique Van de Velde; Marlies Bekaert; Yves Van Nieuwenhove; Silke Hornemann; Maria Rödiger; Nicole Seebeck; Elisabeth Friedl; Wenke Jonas; G Hege Thoresen; Oliver Kuss; Anke Rosenthal; Volker Lange; Andreas F H Pfeiffer; Annette Schürmann; Bruno Lapauw; Natalia Rudovich; Olga Pivovarova; D Margriet Ouwens
Journal:  Diabetologia       Date:  2018-05-12       Impact factor: 10.122

Review 3.  Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.

Authors:  Timon E Adolph; Christoph Grander; Felix Grabherr; Herbert Tilg
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

4.  The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.

Authors:  Ilse M Schrover; Yolanda van der Graaf; Wilko Spiering; Frank Lj Visseren
Journal:  Eur J Prev Cardiol       Date:  2018-07-27       Impact factor: 7.804

5.  Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis.

Authors:  Paul Horn; Christian von Loeffelholz; Franziska Forkert; Sven Stengel; Philipp Reuken; René Aschenbach; Andreas Stallmach; Tony Bruns
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

6.  Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis.

Authors:  Lena-Maria Levin; Henry Völzke; Markus M Lerch; Jens-Peter Kühn; Matthias Nauck; Nele Friedrich; Stephanie Zylla
Journal:  Endocr Connect       Date:  2019-08-01       Impact factor: 3.335

Review 7.  Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis.

Authors:  Qian Ren; Hongya Wang; Yan Zeng; Xia Fang; Mei Wang; Dongze Li; Wei Huang; Yong Xu
Journal:  Lipids Health Dis       Date:  2022-03-02       Impact factor: 3.876

Review 8.  Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

Authors:  Vera Francisco; Maria Jesus Sanz; José T Real; Patrice Marques; Maurizio Capuozzo; Djedjiga Ait Eldjoudi; Oreste Gualillo
Journal:  Biology (Basel)       Date:  2022-08-19

9.  Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.

Authors:  Pia Fahlbusch; Birgit Knebel; Tina Hörbelt; David Monteiro Barbosa; Aleksandra Nikolic; Sylvia Jacob; Hadi Al-Hasani; Frederique Van de Velde; Yves Van Nieuwenhove; Dirk Müller-Wieland; Bruno Lapauw; D Margriet Ouwens; Jorg Kotzka
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

10.  Serum and adipose tissue chemerin is differentially related to insulin sensitivity.

Authors:  Monika Karczewska-Kupczewska; Agnieszka Nikołajuk; Magdalena Stefanowicz; Natalia Matulewicz; Irina Kowalska; Marek Strączkowski
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.